Know Cancer

forgot password

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

Phase 2
60 Years
Open (Enrolling)
Stem Cell Transplantation, Leukemia, Lymphoma

Thank you

Trial Information

Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies

The Study Drugs:

Thiotepa and busulfan are designed to bind to DNA (genetic material of cells), which may
cause cancer cells to die. They are commonly used in stem cell transplants.

Clofarabine is designed to interfere with the growth and development of cancer cells.

Study Drug Administration:

If you are found to be eligible to take part in this study, you will begin receiving the
study drugs before you receive the stem cell transplant.

On Day -8 (8 days before you receive the stem cell transplant), you will receive thiotepa
through a central venous catheter (CVC) over 2 hours. A CVC is a sterile, flexible tube that
will be placed into a large vein while you are under local anesthesia. Your doctor will
explain this procedure to you in more detail, and you will be required to sign a separate
consent form for this procedure.

On Day -7, you will receive busulfan through a CVC. This dose of busulfan is a low level
"test" dose to check how your blood levels change over time. This information will be used
to decide the next dose level of busulfan.

Blood (about 1 teaspoon each time) will be drawn 6-11 times total over Days -7 and -5 for
pharmacokinetic (PK) testing. PK testing measures the amount of busulfan in the body at
different time points. This PK testing will be done to find the dose of busulfan needed for
your body size on the other days that you receive busulfan. A heparin lock line will be
placed in a vein to lower the number of needed sticks performed for draws. If you cannot
have the blood level tests performed for any reason, you will receive the standard busulfan

On Days -6, -5, -4, and -3, you will receive clofarabine through a CVC over 1 hour.

On Days -5, -4, and -3, you will receive busulfan through a CVC over 3 hours.

On Days -4 and -3 you will also receive antithymocyte globulin (ATG) by vein over 4 hours.
This will help to reduce the risk of your body rejecting the transplant. If your transplant
will involve haploidentical stem cells, you will not receive ATG on Days -4 and -3.

On Days -2 and -1, you will "rest," which means you will not be given any drugs, but your
CVC will remain in place.

Stem Cell Transplant:

On Day 0, you will have an allogeneic or haploidentical stem cell transplant through the
CVC. Allogeneic stem cells come from a donor whose cells closely match your own cells.
Haploidentical stem cells come from a donor whose cells do not match your own cells as
closely, but they are specially processed to help prevent graft versus host disease (GVHD).

Receiving stem cells is similar to receiving a blood transfusion. The time required to
receive the stem cells will depend on the type of cells you are receiving. Receiving cord
blood stem cells can take several minutes. Receiving bone marrow and blood stem cells may
take several hours.

You will receive G-CSF (filgrastim) (which helps to produce white blood cells) as an
injection under the skin once a day, starting 1 week after the transplant, until your blood
cell levels return to normal.

You will receive drugs (mycophenolate mofetil (MMF), tacrolimus and/or methotrexate) to help
prevent side effects, such as GVHD. You will receive methylprednisolone if you develop GVHD.

You will stay in the hospital for about 4 weeks after the stem cell transplantation.

If you had a haploidentical stem cell transplant, on Days 3 and 4 after your stem cell
transplant, you will receive cyclophosphamide through a CVC over 30-60 minutes. Mesna will
be given by vein at the same time you are given each dose of cyclophosphamide, to help
protect your bladder from bleeding.

Study Visits:

Beginning on Day -9, once a day while you are in the hospital:

- You will have a physical exam, including measurements of your vital signs.

- You will be asked if you have had any side effects.

- Blood (about 4 tablespoons) will be drawn to test your blood cell counts. Two (2) times
a week, this blood will be also be used for routine tests.

After you are out of the hospital, 2 times a month until it has been 100 days after the

- You will have a physical exam, including measurements of your vital signs and weight.

- You will be asked if you have had any side effects.

- Blood (about 4 tablespoons) will be drawn for routine tests.

About 1, 3, 6, and 12 months after the transplant, blood (about 4 tablespoons) will be drawn
to check the status of the disease. You will also have bone marrow aspirations to check the
status of the disease. You will also have a physical exam.

If the doctor thinks it is necessary, you may have extra tests and procedures.

Length of Study:

You will be on study for about 1 year. You will be taken off study if the disease gets worse
or needs further treatment.


If you live close to M. D. Anderson, you will return to the clinical once every several
months for a physical exam. At these visits, blood (about 3 teaspoons) will be drawn for
routine tests.

You and/or your local doctor will be called every several months and asked about your health
status and if the leukemia or MDS has come back.

This is an investigational study. Thiotepa and clofarabine are FDA approved and
commercially available for the treatment of leukemia. Busulfan is FDA approved and
commercially available for use in stem cell transplantation. The combination of thiotepa,
clofarabine, and busulfan together with a stem cell transplant is investigational.

Up to 60 participants will take part in this study. All will be enrolled at M. D. Anderson.

Inclusion Criteria:

1. Diagnosed with one of the following diseases:

2. Acute myelogenous leukemia (AML) in induction failure, relapse, past first remission,
or CR1 considered at risk for relapse

3. Myelodysplastic syndromes with International Prognostic Scoring System score (IPSS
score) >/= 2 or myelodysplasia that has not responded to chemotherapy

4. Biphenotypic leukemia

5. Acute lymphocytic leukemia with induction failure, first complete remission with high
risk cytogenetics (e.g. Philadelphia positive chromosome, t(4:11) Remission requiring
more than 2 chemotherapy to achieve remission, or any stage beyond CR1

6. Chronic Myelogenous Leukemia (CML): second chronic phase, accelerated phase or blast
crises with less than 10% blasts in the bone marrow, or CR1 and resistance to Gleevec
or other tyrosine kinase inhibitors

7. Non-Hodgkin's Lymphoma - induction failures, second or third complete remission, or
relapse (including relapse post autologous hematopoietic stem cell transplant)

8. Hodgkin's disease - induction failure, second or later complete remission, or relapse
(including relapse post autologous hematopoietic stem cell transplant).

9. Chronic Lymphocytic Leukemia that has failed induction therapy or Rai Stages 2-4

10. Related or unrelated donor which is HLA-matched or mismatched in 1 HLA A, B, C, DR,
or DQ locus is acceptable (i.e. >/= 9/10 matched related or unrelated donor, matched
with molecular high-resolution technique per current std. for BMT program). Cord
blood units must match patient at 4, 5, or 6/6 HLA class 1 serological & II molecular
antigens with a min. of 2 * 10e7 TNC/kg recipient weight in the pre-thawed fraction.
For patient lacking a matched related or unrelated donor or acceptable cord blood
unit(s), a related haploidentical donor ( may be used.

11. Age
12. Lansky performance score >/= 50% for patients performance status score of 0-2 for patients > 16 years of age.

13. Cardiac function - left ventricular ejection fraction >/= 40%.

14. Pulmonary function - diffusion capacity of at least 50% predicted. Children unable to
perform pulmonary function tests (e.g. less than 7 years old) pulse oximetry of >/=
92% on room air.

15. Serum creatinine < 1.6 mg/dL or creatinine clearance >/= 50 ml/min.

16. Serum glutamic-pyruvic transaminase (SGPT) normal.

17. Written informed consent and assent as is age appropriate.

18. No active infection.

Exclusion Criteria:

1. Pregnancy in women of child bearing potential (pregnancy test performed within 2
weeks of study entry).

2. HIV positive (highly immunosuppressive treatment)

3. Active Central Nervous System (CNS) leukemia

4. Chronic or active Hepatitis B or Hepatitis C. If questions about liver health discuss
with PI and strongly consider liver biopsy.

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Relapse-free Survival Rate

Outcome Description:

Number of participants out of total participants without detection of histologic diagnosis of recurrent disease on day 100 following stem cell transplant.

Outcome Time Frame:

100 days post-transplant

Safety Issue:


Principal Investigator

Laura L. Worth, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

UT MD Anderson Cancer Center


United States: Institutional Review Board

Study ID:




Start Date:

March 2009

Completion Date:

Related Keywords:

  • Stem Cell Transplantation
  • Leukemia
  • Lymphoma
  • Cancer
  • Blood And Marrow Transplantation
  • Stem Cell
  • Leukemia
  • Lymphoma
  • Pediatrics
  • Bone marrow
  • Lymph node system
  • Allogeneic Stem Cell Transplant
  • ASCT
  • Busulfan
  • Busulfex
  • Myleran
  • Clofarabine
  • Clofarex
  • Clolar
  • Thiotepa
  • Antithymocyte globulin
  • ATG
  • Thymoglobulin
  • G-CSF
  • Filgrastim
  • Neupogen
  • Leukemia
  • Lymphoma



UT MD Anderson Cancer CenterHouston, Texas  77030